India, May 6 -- BioCardia, Inc. (BCDA) has announced the initiation of patient enrollment at the University of Wisconsin-Madison for its ongoing CardiAMP HF II Phase 3 pivotal trial, marking a key milestone in the company's clinical development program for ischemic heart failure.
The CardiAMP HF II study is evaluating the safety and efficacy of CardiAMP Cell Therapy, a minimally invasive, autologous bone marrow-derived cell therapy for patients with ischemic heart failure with reduced ejection fraction or HFrEF and elevated NTproBNP levels-a biomarker associated with increased cardiac stress.
The study is designed to enroll 250 patients and builds on findings from the earlier CardiAMP HF trial, where those with elevated NT-proBNP experien...